Itraconazole or Amphotericin B for Talaromycosis
- 5 October 2017
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 377 (14), 1402-1403
- https://doi.org/10.1056/nejmc1709123
Abstract
Le et al. (June 15 issue)1 report that amphotericin B was superior to itraconazole in the treatment of talaromycosis and that the rates of adverse events were higher with amphotericin B use. However, some issues need to be discussed. The investigators did not report severity of illness or preexisting medical conditions. The treatment of talaromycosis depends on the severity of the infection, because itraconazole is recommended for milder forms of talaromycosis and amphotericin B or voriconazole for more severe forms.2 The efficacy of treatment in both study groups can be misleading if, for instance, patients were not adequately treated or were overtreated on the basis of the severity of their infection. The presence of preexisting medical conditions could influence treatment outcomes, because patients with these conditions may be more susceptible to negative outcomes.Keywords
This publication has 7 references indexed in Scilit:
- A Trial of Itraconazole or Amphotericin B for HIV-Associated TalaromycosisThe New England Journal of Medicine, 2017
- Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted StatesAntimicrobial Agents and Chemotherapy, 2015
- 10 Travel-related opportunistic infectionsHIV Medicine, 2011
- Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered AgentsClinical Infectious Diseases, 2009
- Clinical Practice Guidelines for the Management of Patients with Histoplasmosis: 2007 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2007
- Reviews Of Anti‐infective Agents: New Agents for the Treatment of Fungal Infections: Clinical Efficacy and Gaps in CoverageClinical Infectious Diseases, 2006
- Reduced oral itraconazole bioavailability by antacid suspensionJournal of Clinical Pharmacy & Therapeutics, 2005